Method of preparing autologous cells and methods of use for therapy
First Claim
1. A method of treating a patient having a disease selected from the set of heart failure, myocardial ischemia, myocardial infarction, peripheral vascular disease, and an autoimmune disease, said method comprising injecting an expanded population of mesenchymal stem cells into the tissue of the patient in or near the target area of the disease thereby ameliorating an effect of the disease, said therapeutic cell population having been expanded in autologous medium as follows:
- harvesting blood from a donor in two visits separated between one and three weeks;
harvesting bone marrow cells from the donor;
forming a culture medium from said blood that contains no animal serum and comprises 10% autologous serum obtained from the donor; and
expanding a population of mesenchymal stem cells from the bone marrow cells in the culture medium.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy.
32 Citations
7 Claims
-
1. A method of treating a patient having a disease selected from the set of heart failure, myocardial ischemia, myocardial infarction, peripheral vascular disease, and an autoimmune disease, said method comprising injecting an expanded population of mesenchymal stem cells into the tissue of the patient in or near the target area of the disease thereby ameliorating an effect of the disease, said therapeutic cell population having been expanded in autologous medium as follows:
-
harvesting blood from a donor in two visits separated between one and three weeks; harvesting bone marrow cells from the donor; forming a culture medium from said blood that contains no animal serum and comprises 10% autologous serum obtained from the donor; and expanding a population of mesenchymal stem cells from the bone marrow cells in the culture medium. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
Specification